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Abstract 
Background 
Lysosomal dysfunction is thought to be a prominent feature in the pathogenetic events 
leading to Parkinson’s disease (PD). This view is supported by the evidence that mutations in 
GBA gene, coding the lysosomal hydrolase β-glucocerebrosidase (GCase), are a common 
genetic risk factor for PD. Recently, GCase activity has been shown to be decreased in 
substantia nigra and in cerebrospinal fluid of patients diagnosed with PD or dementia with 
Lewy Bodies (DLB). Here we measured the activity of GCase and other endo-lysosomal 
enzymes in different brain regions (frontal cortex, caudate, hippocampus, substantia nigra, 
cerebellum) from PD (n = 26), DLB (n = 16) and age-matched control (n = 13) subjects, 
screened for GBA mutations. The relative changes in GCase gene expression in substantia 
nigra were also quantified by real-time PCR. The role of potential confounders (age, sex and 
post-mortem delay) was also determined. 
Findings 
Substantia nigra showed a high activity level for almost all the lysosomal enzymes assessed. 
GCase activity was significantly decreased in the caudate (−23%) and substantia nigra 
(−12%) of the PD group; the same trend was observed in DLB. In both groups, a decrease in 
GCase mRNA was documented in substantia nigra. No other lysosomal hydrolase defects 
were determined. 
Conclusion 
The high level of lysosomal enzymes activity observed in substantia nigra, together with the 
selective reduction of GCase in PD and DLB patients, further support the link between 
lysosomal dysfunction and PD pathogenesis, favoring the possible role of GCase as 
biomarker of synucleinopathy. Mapping the lysosomal enzyme activities across different 
brain areas can further contribute to the understanding of the role of lysosomal derangement 
in PD and other synucleinopathies. 
Keywords 
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Introduction 
The identification of the underlying causes of Parkinson’s disease (PD) is a major challenge, 
since in most instances, cases present with sporadic disease. The discovery of the genetic 
determinants of PD would be a major step forward in describing the underlying etiology of 
the disorder and also in identifying possible therapeutic strategies [1]. Mutations in the GBA 
gene, encoding for the lysosomal hydrolase β-glucocerebrosidase (GCase, EC = 3.2.1.45) 
cause Gaucher disease (GD) a rare lysosomal storage disorder, and represent a common risk 
factor for PD [2-4]. Patients carrying GBA loss of function mutations have a five-fold 
increased risk of developing PD with respect to non-carriers [3], and may show a similar 
phenotype to idiopathic PD. The GCase substrate, glucosylceramide, stabilizes soluble 
oligomeric α-syn species [5]. As a consequence, GCase deficiency may contribute to α-syn 
aggregation and accumulation. GCase deficiency has been identified in post mortem brain 
from patients diagnosed with PD either with or without GBA mutations, the decrease being 
most evident in the substantia nigra, cerebellum and cortex of PD patients [6,7]. This non-
selective loss of GCase activity irrespective of mutation status may either represent a global 
defect in lysosomal enzymes in PD, or may simply represent the presence of other 
pathologies such as neuronal loss leading to deficiency. 
The activity of GCase and other lysosomal enzymes can also be reliably measured in 
cerebrospinal fluid (CSF) [8]. The reduction of GCase activity has been found also in the 
cerebrospinal fluid (CSF) of PD patients when compared to neurological controls [9-11] and 
in fibroblasts from patients with GD or PD carrying GBA mutations [12]. Interestingly, other 
lysosomal enzymes involved in different degradation pathways, were also found to be altered 
in PD patients diagnosed with PD. An increased β-hexosaminidase activity, a lysosomal 
enzyme able to hydrolyze the GM2 ganglioside, has been found in CSF and fibroblasts of PD 
patients [11,12]. Another study showed increased activity of cathepsin E and β-galactosidase 
in CSF of de-novo PD patients while α-fucosidase activity was significantly decreased [13]. 
Together, these findings suggest that there may be a more widespread dysfunction of 
lysosomal enzymes in PD and related disorders. 
Here we determined the specific activity of several endo-lysosomal enzymes, namely β-
hexosaminidase, α-fucosidase, β-mannosidase, α-mannosidase, β-galactosidase, β-
glucocerebrosidase and cathepsin E, in different brain areas of PD patients, age-matched 
controls and, for some brain areas, of patients diagnosed with dementia with Lewy bodies 
(DLB). Our aims were to map the activity of these lysosomal enzymes in different human 
brain regions and also to evaluate the occurrence of lysosomal dysfunction not only in PD but 
also in another synucleinopathy, DLB. This would provide the necessary information to 
determine if lysosomal dysfunction is widespread in PD, or if there is a relatively selective 
loss of GCase. 
Findings 
We utilized a large series of clinically and neuropathologically verified cases of PD and DLB 
and age matched control cases. In Table 1 the demographic characteristics of the patients 
included in the study are reported. Post-mortem brain tissue was analyzed for lysosomal 
enzyme activity, GBA genotype and GBA mRNA expression. GBA sequencing was 
performed to verify the presence of pathological mutations on GBA gene. The results showed 
that our cohort was composed mainly of patients and controls without GBA mutations. Only 
two out of 26 PD patients were heterozygous for pathogenic GBA mutations. One patient 
carried the L444P mutation while the other one carried the IVS2 + 1G > A mutation. The 
remaining PD and DLB patients and control subjects were wild type for the GBA gene 
(CTRL =9, PD = 23, DLB = 15). GBA genotype was not available in 4 controls, 1 PD and 1 
DLB. Using hierarchical clustering analysis, we compared the lysosomal enzyme activities 
across different brain areas (Figure 1a). The substantia nigra and the hippocampus clustered 
together in the analysis, globally showing a high level of almost all the enzyme activities. 
GCase was the exception, showing low levels in substantia nigra but only in the pathological 
groups, while its levels were high in frontal cortex. The caudate clustered independently from 
the other areas and showed the lowest levels of the measured activities. Notably, the 
differences among the brain areas were greater than the differences between PD, DLB 
patients and control subjects. 
Table 1 Demographic characteristics of the subjects included in the study 
Demographics Controls PD DLB 
N 13 26 16 
Sex (M) 6 (46%) 18 (69%) 12 (75%) 
Age 77.0 (±8.0), 78 (65–
89) 
76.4 (±6.4), 77 (64–89) 76.9 (±5.7), 77 (66–
88) 
Post mortem delay 18.2 (±6.9), 17 (8–30) 26.2 (±12.8), 24 (7–64) 
* 
18.5 (±8.6), 18 (4–31)
Alzheimer Braak 
stage 
1.9 (±1.4), 2 (0–4) 2.1 (±1.5), 2 (0–5) * 2.6 (±1.1), 2.5 (0–4) 
Means (±SD), medians (min-max). *p < 0.05 with Wilcoxon two groups test or Fisher’s exact 
test. Braak stage is referred to the Alzheimer’s neurofibrillary tangle score. 
Figure 1 Lysosomal enzyme activities in human brain. a) Cluster analysis of lysosomal 
enzyme activities. Lysosomal specific activities were normalized with respect to their means 
and standard deviations, while patients were summarized using their respective diagnostic 
group; b) Boxplots of the GCase specific activity across different brain areas. In the table 
below the figure, the significant comparisons are reported according to the statistical model 
used; c) mRNA levels of GBA gene. 2-ΔCT values normalized by housekeeping genes 
GAPDH and SDHA. *p < 0.05 using Wilcoxon two groups test and nonparametric 
ANCOVA model with adjustment for post mortem delay. 
The comparison of the mean levels of lysosomal enzyme activities in the three groups is 
reported in Additional file 1: Table S1. We first evaluated the effect of post mortem delay as 
a confounder in the different comparisons. No significant association was found between 
postmortem delay and lysosomal enzymes activity when it was considered as a potential 
confounder (data not shown). GCase specific activity in substantia nigra and caudate was 
significantly lower in PD patients when compared to control subjects (p < 0.01 and p < 0.05 
respectively, Figure 1b). In DLB patients, GCase activity was also reduced, but the difference 
was not significant (Additional file 1: Table S1). GCase activity did not change significantly 
in the other brain regions in any of the diagnostic groups (Figure 1b), suggesting a selective 
loss in the nigrostriatal system. The two patients carrying GBA mutations showed detectable 
GCase activity, with values within the range of the PD and DLB patients without mutations. 
Exclusion of the two patients from the analysis did not change the significance of the final 
results (data not shown). 
To evaluate if the decrease in GCase activity was due to a change in gene expression we 
performed qPCR on GBA mRNA in the substantia nigra. mRNA levels of GBA gene, 
normalized against GAPDH, were significantly lower in PD and DLB compared to controls 
(p < 0.05). The same result was found with respect to the subunit A of the succinate 
dehydrogenase complex (SDHA) (Figure 1c). 
Other enzymatic activities were changed in different brain areas. In particular, α-fucosidase 
activity in frontal cortex was significantly lower in PD compared to controls (p < 0.01), while 
its activity in DLB patients did not change significantly (Additional file 1: Figure S1). 
Interestingly, α-mannosidase activity was increased in frontal cortex only in DLB patients 
(Additional file 1: Figure S1). 
We also performed correlation analysis between the enzyme activities and Alzheimer’s 
neurofibrillary pathology expressed as Braak stage. No significant associations were found 
for any of the enzyme activities tested (data not shown). 
Discussion 
GCase is recognized as an important risk factor for PD and DLB. A recent multicenter study 
found a more significant association of GBA mutations with DLB compared to PD with 
dementia [14]. In this study we mapped the activity of a series of endo-lysosomal enzymes in 
post mortem brain tissue of PD and DLB patients, and compared these with elderly 
pathologically normal control brains from patients. We confirm that GCase specific activity 
is reduced in PD brains, especially in substantia nigra and that this reduction was also present 
in DLB patients although to a lesser extent. Interestingly, the expression of GCase at mRNA 
level was also reduced in the substantia nigra of both synucleinopathies. Our results confirm 
previous reports on the deregulation of GCase in PD [6,7]. In PD patients carrying GBA 
mutations, GCase activity has been found to be reduced in all the brain areas analyzed with 
exception of the cortex [6]. Recently, in sporadic PD, GCase activity and protein expression 
were found to be decreased in the anterior cingulate and occipital cortex, where accumulation 
of α-synuclein occurs during the early phases of the disease [7]. GCase activity decrease in 
these two regions was associated with a reduced lysosomal chaperone-mediated autophagy 
and decreased ceramide levels [7]. 
It is worth noting that in the study of Gegg et al. [6] mRNA levels of GCase were unchanged, 
while in Murphy et al. [7] GCase expression was reduced. In our study, measuring GCase 
mRNA expression in substantia nigra of PD and DLB patients, we also identified a 
significant reduction of GCase mRNA in both PD and DLB. This decrease was paralleled by 
a significant reduction of GCase activity (PD > DLB). Previous work on DLB brains also 
showed a trend in reduction of GCase activity in patients without GBA mutation, while in 
GBA mutations carriers the activity of the enzyme was drastically reduced with respect to 
control subjects [15]. In this study, the low number of patients carrying heterozygous GBA 
mutations prevented us from finding any significant relationship between GBA genotype and 
GCase activity. Nevertheless, we cannot exclude that heterozygous GBA mutations might 
contribute to the reduction of GCase activity in PD. 
With respect to the other lysosomal enzymes considered in this study, we found a significant 
reduction of α-fucosidase activity in the frontal cortex of PD patients compared to control 
subjects, while in DLB the reduction was not significant. α-Fucosidase is responsible for the 
hydrolysis of α-1,6-fucose residues from glycoproteins and has been previously found to be 
reduced in CSF from de-novo PD patients [13]. The possible involvement of α-fucosidase in 
PD pathogenesis is currently unknown, however brain protein fucosylation is regarded as an 
important way for regulating different processes such as neurite outgrowth and synaptic 
plasticity [16]. Defective degradation of fucose residues in proteins may contribute to a 
deregulation of these processes and/or accumulation of undegraded substrates in lysosomes. 
In a study by McNeil and colleagues other lysosomal enzymes were altered in fibroblast from 
PD patients with GBA mutation [12]. Cathepsin D and β-hexosaminidase showed increased 
activity in PD patients fibroblasts, possibly supporting a global deregulation of lysosome 
functioning. In the present study, the activity of β-hexosaminidase did not show significant 
change in any of the brain regions assessed in the three experimental groups. Overall, 
however, we identified minimal changes in other lysosomal enzymes in PD or DLB, 
suggesting that the defect in GCase may be selective in PD and DLB. 
Globally, we found that the activity of the lysosomal enzymes tested was higher in substantia 
nigra and hippocampus with respect to the other brain areas. This result is particularly 
interesting because it highlights the important role of the lysosome system in the metabolism 
of substantia nigra. It might be possible that, in this region, lysosomal metabolism is more 
active due to the elevated oxidative stress taking place in this brain area, with the production 
of oxidized proteins and lipids [17,18]. A failure of the lysosomal system may trigger the 
accumulation of specific substrates of lysosomal hydrolases and proteases, including α-
synuclein, as shown in animal and cell models of GCase inhibition [19,20]. 
In conclusion, we have mapped the lysosomal enzyme activity in two types of 
synucleinopathies. The GCase deficiency found in both diseases and specifically present in 
PD at two different regulation levels (i.e. mRNA and activity) supports the hypothesis of a 
common mechanism of GCase reduction in the pathogenesis of synucleinopathies, with a 
strong link to lysosome dysfunction. 
Methods 
All aspects of this study were approved through the local Ethics Committee of the University 
of Perugia and the Newcastle upon Tyne Research Ethics Committee. Our study utilized 55 
post-mortem brains, 26 diagnosed with PD, 16 with DLB and 13 controls without any 
neurodegenerative disease (age and gender matched). Brain tissue was obtained from the 
Newcastle Brain Tissue Resource (NBTR) at Newcastle University, UK, from individuals 
with a clinical diagnosis of Parkinson’s disease or dementia with Lewy bodies following 
informed consent from donors and with assent from the next of kin. Tissue from individuals 
without a history of cognitive impairment or movement disorder served as controls. 
Neuropathological assessment was performed according to standardized neuropathological 
diagnostic procedures [21] and confirmed the presence of Parkinson’s disease pathology and 
pathological changes of dementia with Lewy bodies, or an absence of significant 
neuropathology in control cases. For each patient, samples of snap frozen hippocampus, 
substantia nigra, putamen, frontal cortex and caudate were used. GBA genotyping was carried 
out according to Kurzawa-Akanbi and colleagues [15]. 
Enzymatic assays 
Brain tissues were thawed and lysed on ice in 50 mM phosphate buffer pH 7.0, containing 
150 mM NaCl, 5% w/v, using an Ultra-turrax. 0.1% NP-40 detergent was added and 
homogenized tissues were sonicated for 30 seconds on ice at 20 Watt. The samples were kept 
on ice for 30 minutes and centrifuged for 10 minutes at 16,000xg and the supernatants were 
used for assay. The activities of the lysosomal enzymes β-hexosaminidase, α-fucosidase, β-
mannosidase, α-mannosidase, β-galactosidase, β-glucorecebrosidase and cathepsin E were 
determined as previously described [8,11]. All of the activities were measured in triplicate. 
One unit (U) of enzyme activity was defined as the amount of enzyme that hydrolyses 1 pmol 
of substrate/min at 37°C. 
mRNA levels of GBA gene 
Total RNA was extracted from substantia nigra tissue using standard methods and the relative 
changes in GBA gene expression were determined by qPCR via relative quantification using 
GAPDH and SDHA as housekeeping genes (Applied Biosystem 7300, TaqMan gene 
expression assay, probe numbers GBA: Hs00986836_g1, SDHA: Hs00188166_m1, GAPDH: 
Hs02758991_g1). The 2-ΔCT method [22] was used to calculate relative changes in gene 
expression determined from the real-time quantitative PCR analysis. 
Data analysis 
The R software [23] was used for statistical analyses. Continuous variables are presented as 
means (±standard deviations) and medians (ranges). Categorical variables are presented as 
count and percentages. Hierarchical clustering analysis was used to compare the lysosomal 
enzyme activities across different brain areas. Differences between patients and controls were 
assessed using ANOVA for both comparing lysosomal enzymes activities and GBA mRNA 
expression. Dunnett’s post-hoc test was used for multiple comparisons. ANCOVA was 
performed for testing the confounding effects of post-mortem delay on the relationships 
between lysosomal enzymes activity or GBA mRNA expressions and disease. A p-value 
≤0.05 was considered significant in all the analyses. 
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